Not a good buy right now: trend remains bearish (SMA_200 > SMA_20 > SMA_5) with weak forward-return setup (similar-pattern stats point to ~-3% over the next week/month).
No Intellectia edge today (no AI Stock Picker or SwingMax trigger), so there’s no high-conviction timing signal to override the bearish tape.
Fundamental/news backdrop is not providing a near-term catalyst (no fresh news; prior Phase 3 failure still overhangs sentiment).
For an impatient buyer unwilling to wait for cleaner confirmation, the risk/reward is unattractive at current levels (~3.96) given nearby resistance overhead and limited positive catalysts.
Technical Analysis
Price/location: 3.96 is below the pivot (4.082) and sitting just above key supports S1 (3.971) and S2 (3.903) — weak positioning with little buffer.
Trend: Bearish moving average stack (SMA_200 > SMA_20 > SMA_5) signals a sustained downtrend.
Momentum: MACD histogram is slightly positive (0.00948) but positively contracting, implying upside momentum is fading (often a weak/bearish tell in downtrends).
RSI: RSI_6 at 30.897 is near oversold; this can support short bounces, but by itself it’s not a buy signal without trend reversal confirmation.
Levels to watch: Resistance at 4.082 (pivot) then 4.193 (R1); failure to reclaim/hold above pivot keeps bears in control.
Probabilistic trend (pattern analogs): 60% chance of ~flat next day (+0.09%), but downside skew over the next week/month (-3%).
can allow a short technical bounce if support (3.97/3.
holds.
Neutral/Negative Catalysts
Major clinical overhang: Phase 3 social anxiety disorder failure increased the risk profile materially.
Technical structure remains bearish with resistance overhead (4.08–4.19 zone).
No fresh news/catalysts in the past week to re-rate the stock.
Similar-pattern forward-return stats point to continued drift lower over the next week/month (~-3%).
Trading trends: hedge funds neutral (no significant last-quarter trend) and insiders neutral (no significant last-month trend) — no “smart money” urgency showing up.
Financial Performance
Latest quarter: 2026/Q1.
Revenue: 0 (no growth; effectively pre-revenue).
Net income: -9,906,504 (loss); reported as up 1130.95% YoY, which indicates materially worse profitability versus prior year.
EPS: -4.41 (still deeply negative).
Gross margin: 0 (consistent with no revenue).
Takeaway: financials do not show improving operating momentum; valuation support is hard to argue without a clear clinical/strategic catalyst.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Most recent analyst action (2025-12-05): H.C. Wainwright kept a Buy but cut price target sharply to $7 from $21.
Rating/target trend: the Buy rating remains, but the dramatic target reduction signals a clear deterioration in confidence and a reset of expectations.
Wall Street pro view (pros): lingering value from positive Phase 2b PTSD data could support future upside if development progresses.
Wall Street con view (cons): Phase 3 failure meaningfully increased risk and undermines near-term credibility, making the stock harder to underwrite until a new catalyst emerges.
Politicians/influential figures: No recent congress trading data available (last 90 days).
Wall Street analysts forecast NEUP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEUP is 9.77 USD with a low forecast of 2.3 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast NEUP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEUP is 9.77 USD with a low forecast of 2.3 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.995
Low
2.3
Averages
9.77
High
20
Current: 3.995
Low
2.3
Averages
9.77
High
20
H.C. Wainwright
Buy
downgrade
$21 -> $7
AI Analysis
2025-12-05
Reason
H.C. Wainwright
Price Target
$21 -> $7
AI Analysis
2025-12-05
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Neuphoria Therapeutics to $7 from $21 and keeps a Buy rating on the shares. The firm says the company is "caught between a rock and a hard place right now." With the Phase 3 social anxiety disorder failure, Neuphoria's risk profile "has increased significantly," the anlayst tells investors in a research note. However, the firm says the positive Phase 2b post-traumatic stress disorder data still provides value to the company.
Lucid Capital
Elemer Piros
Buy -> Neutral
downgrade
$81
2025-10-21
Reason
Lucid Capital
Elemer Piros
Price Target
$81
2025-10-21
downgrade
Buy -> Neutral
Reason
Lucid Capital analyst Elemer Piros downgraded Neuphoria Therapeutics to Neutral from Buy with a price target of $2.30, down from $81, after the Phase 3 AFFIRM-1 trial of BNC210 for the acute treatment of social anxiety disorder failed to meet its primary endpoint. The study also did not show statistically significant results across secondary endpoints, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NEUP
